Mihran Yenikomshian
Education
M.B.A., F.W. Olin Graduate School of Business, Babson College; B.A., quantitative economics and computer science, Tufts University
Summary of Experience
Mr. Yenikomshian specializes in technology, data analysis, and economic modeling, and has consulted on technical, economic, and strategic issues to companies in a variety of industries, including computer software and technology, cybersecurity, blockchain and cryptocurrency, pharmaceuticals, and medical insurance. He has extensive experience analyzing technical issues, such as those relating to software and internet technologies, and translating them to a lay audience. Mr. Yenikomshian has analyzed the flows of data from user devices to third-party service providers such as analytics and advertising companies. He testified on behalf of the US Department of Justice in its criminal indictment of Jitesh Thakkar, who allegedly designed and sold a software program that assisted a commodities trader who was engaged in spoofing. In this matter, Mr. Yenikomshian’s role was to determine whether the software program that Thakkar produced operated the way that the trader’s requirements document had specified. He provided a detailed demonstration of how the requirements for the order types were translated into a software program by walking the court through the actual lines of code that implemented the requirements. Mr. Yenikomshian has also conducted numerous other software code reviews in a range of matters. In addition, he has developed interactive software tools to help clients make strategic decisions. Mr. Yenikomshian is a member of the American Bar Association and serves as co-chair of its Biotechnology, Healthcare Technology, and Medical Devices Committee. Previously, he served as co-chair of its Big Data Committee and Data Science Working Group, as well as vice chair of its Artificial Intelligence and Robotics Committee. Prior to joining Analysis Group, Mr. Yenikomshian was a partner in a software development and staffing technology firm.
-
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
BMC Ophthalmology, 2023
2023Karpecki P, Barghout V, Schenkel B, Huynh L, Khanal A, Mitchell B, Yenikomshian M, Zanardo E, Matossian C
-
Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis
Advances in Therapy, 2023
2023Cheng WY, Fishman J, Yenikomshian M, Mahendran M, Kunzweiler C, Vu JD, Duh MS
-
Patient-centric assessment of rheumatoid arthritis using a smartwatch and bespoke mobile app in a clinical setting
Scientific Reports, 2023
2023Hamy V, Llop C, Yee CW, Garcia-Gancedo L, Maxwell A, Chen WH, Tomlinson R, Bobbili P, Bendelac J, Landry J, DerSarkissian M, Yenikomshian M, Mody EA, Duh MS, Williams R
-
Mitigating Antitrust Concerns when Competitors Share Data Using Blockchain Technology
Harvard Journal of Law & Technology, Volume 34, Digest Spring 2021
2021Arcelus A, Nocera N, Yenikomshian M
-
Health Cos. Can Reduce FCA Risk by Leveraging Data
Law360, 2021
2021Jenny B, Yenikomshian M, Greenberg PE
-
Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center
The Oncologist, 2021
2021Patel AK, Abhyankar R, Brais LK, Duh MS, Barghout VE, Huynh L, Yenikomshian MA, Ng K, Fuchs CS
-
Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population
Advances in Therapy, 2021
2021Cheng WY, Sarda SP, Mody-Patel N, Krishnan S, Yenikomshian M, Mahendran M, Lejeune D, Yu LH, Duh MS
-
Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
Oncologist, 2020
2020Patel AK, Barghout V, Yenikomshian MA, Germain G, Jacques P, Laliberté F, Duh MS
-
Modeling the potential impact of abuse-deterrent opioids on medical resource utilization
Journal of Medical Economics, 2019
2019Yenikomshian MA, White AG, Carson ME, Jia ZB, Mendoza MR, Roland CL
-
Cardiac arrhythmia detection outcomes among patients monitored with the Zio patch system: a systematic literature review
Current Medical Research and Opinion, 2019
2019Yenikomshian M, Jarvis J, Patton C, Yee C, Mortimer R, Birnbaum H, Topash M
-
Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib
Clinical Colorectal Cancer. 2018 Sep;17(3):e531-e539
2018Patel AK, Duh MS, Barghout V, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS
-
Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients
Journal of Opioid Management. Sep/Oct 2017;13(5):291-301
2017Yenikomshian MA, White AG, Carson ME, Garrison LP, Oderda GM, Biskupiak JE, Hlavacek PR, Roland CL
-
A model to quantify potential medical events avoided and cost savings from abuse deterrent opioids
Journal of Pain, 2016
2016White A, Yenikomshian M, Carson M, Masters E, Roland C
-
The epidemiology of herpes zoster and its complications in Medicare cancer patients
BMC Infect Dis. 2015 Feb 27;15(1):106. doi: 10.1186/s12879-015-0810-6
2015Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, Karner P, Duh MS
-
The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk
J Med Econ. 2015 Apr 1:1-9. [Epub ahead of print]
2015Penn MS, Yenikomshian MA, Cummings AK, Klemes A, Damron JM, Purvis S, Beidelschies M, Birnbaum HG
-
April 1, 2022
-
October 12, 2022
-
June 6, 2024
-
April 9, 2024
-
December 1, 2023
-
March 2, 2023
-
May 27, 2022
-
March 29, 2022
-
October 15, 2021
-
August 12, 2021
-
March 16, 2021
-
March 16, 2021